Pulmatrix, Inc. - צמיחת מכירות משנה לשנה (TTM) PULM

The rolling 12-month year-over-year sales growth rate illustrates the revenue dynamics of Pulmatrix, Inc. (PULM), where -100.50 characterizes this valuation parameter. Geopolitical strife is hindering the procurement of rare components and global drug testing. However, steady demand for inhalation therapy in lung treatment ensures consistent revenue. Management is currently adjusting R&D plans while awaiting the results of joint clinical trials.
Pulmatrix, Inc. - פילוחים אנליטיים ומדדי מפתח (PULM)

Outsourcing the production of inhalation agents to external CDMO partners minimizes capital expenditures for Pulmatrix, Inc. regarding facility maintenance. The TTM annual sales growth reflects revenue dynamics over a rolling 12-month period, neutralizing seasonality. Analysis of this chart allows for the identification of real business expansion rates through market noise. A stable trend confirms the resilience of the operating model. The indicator's positive trajectory serves as a signal for long-term capitalization growth.